Friday, May 01, 2020 4:04:20 PM
I responded to this, posted by you:
by asking why you thought the science was hogwash. Is there hope of receiving an answer to that question?
On another topic, which you introduced in your latest post: I agree. You may well be right about the financial maneuvers of Dr. Diwan. Suspicion of his motives and practices is why I've repeatedly said that in spite of my continuing interest in the science and engineering, I cannot recommend investment in NNVC.
Regardless of Dr. Diwan's personal qualities I hope the science and engineering done at NNVC and Theracour is not obscured by continuous mockery. There may be something to all that work, and if so, the world needs to know it, and do something with it.
There's a lot of folks that have been paying attention to the science for a decade and a half and have determined it's hogwash. Namely: Big Pharma, the majority of Wall Street and Yours Truly.
On another topic, which you introduced in your latest post: I agree. You may well be right about the financial maneuvers of Dr. Diwan. Suspicion of his motives and practices is why I've repeatedly said that in spite of my continuing interest in the science and engineering, I cannot recommend investment in NNVC.
Regardless of Dr. Diwan's personal qualities I hope the science and engineering done at NNVC and Theracour is not obscured by continuous mockery. There may be something to all that work, and if so, the world needs to know it, and do something with it.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
